Evidence map›Paper›PMID 33974232›Full record

ArticleMolecular and cellular biochemistry2021

Comprehensive plasma metabolomic and lipidomic analyses reveal potential biomarkers for heart failure.

Juntuo Zhou, Xi Chen, Wei Chen, Lijun Zhong, Ming Cui

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 35 citations in OpenAlex.

  1. Impact of matched samples on domain harmonization in cross-cohort NMR metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2026
    Article
  2. Review
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Juntuo Zhou *Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, No. 49, Hua Yuan North Rd, Hai Dian District, Beijing, 100191, China.
Xi Chen *Department of Pathology, School of Basic Medical Science, Peking University Health Science Center, Beijing, 100191, China.
Wei ChenCenter of Medical and Health Analysis, Peking University Health Science Center, Beijing, 100191, China.
Lijun ZhongCenter of Medical and Health Analysis, Peking University Health Science Center, Beijing, 100191, China. zhonglijun@bjmu.edu.cn.ORCID http://orcid.org/0000-0002-4228-182X
Ming CuiDepartment of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, No. 49, Hua Yuan North Rd, Hai Dian District, Beijing, 100191, China. mingcui@bjmu.edu.cn.
Peking University · CNMinistry of Education of the People's Republic of China · CN

Funding

National Natural Science Foundation of China 81570235Peking University Health Science Center BMU2018PY006
6 · The paper itself

Abstract

Heart failure is a syndrome with symptoms or signs caused by cardiac dysfunction. In clinic, four stages (A, B, C, and D) were used to describe heart failure progression. This study was aimed to explore plasma metabolomic and lipidomic profiles in different HF stages to identify potential biomarkers. Metabolomics and lipidomics were performed using plasma of heart failure patients at stages A (n = 49), B (n = 61), and C+D (n = 26). Analysis of Variance (ANOVA) was used for screening dysregulated molecules. Bioinformatics was used to retrieve perturbed metabolic pathways. Univariate and multivariate receiver operating characteristic curve (ROC) analyses were used for potential biomarker screening. Stage A showed significant difference to other stages, and 142 dysregulated lipids and 134 dysregulated metabolites were found belonging to several metabolic pathways. Several marker panels were proposed for the diagnosis of heart failure stage A versus stage B-D. Several molecules, including lysophosphatidylcholine 18:2, cholesteryl ester 18:1, alanine, choline, and Fructose, were found correlated with B-type natriuretic peptide or left ventricular ejection fractions. In summary, using untargeted metabolomic and lipidomic profiling, several dysregulated small molecules were successfully identified between HF stages A and B-D. These molecules would provide valuable information for further pathological researches and biomarker development.

Indexed as

MetabolomeAgedBiomarkersCase-Control StudiesHeart FailureHumansLipidomicsLipidsMaleMiddle AgedROC CurveBiomarkersLipidsBiomarkerHeart failureLC-MSLipidomicsMetabolic profilingMetabolomics

Identifiers

PMID33974232
OpenAlexW3162183223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.